TEL AVIV, Feb 13 (Reuters) – Israel-based Teva
Pharmaceutical Industries said on Tuesday it had
anticipated and planned for a second generic competitor to its
multiple sclerosis treatment Copaxone to enter the market in
2018.

Read More At Article Source | Article Attribution